Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trialSaye Khoo, Ján Dixon, Lauren Walker et al.|The Lancet Infectious Diseases|2022Cited by 81
Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trialI’ah Donovan-Banfield, Rebekah Penrice-Randal, Hannah Goldswain et al.|Nature Communications|2022Cited by 42
A Randomised -Controlled Phase 2 trial of Molnupiravir in Unvaccinated and Vaccinated Individuals with Early SARS-CoV-2Saye Khoo, Gareth Griffiths, Richard J. Fitzgerald et al.|medRxiv|2022Cited by 3
A randomised-controlled Phase I de-escalation trial of Molnupiravir and Nirmatrelvir/Ritonavir combination for mild-moderate SARS-CoV-2 infectionSaye Khoo, Gareth Griffiths, Richard J. Fitzgerald et al.|medRxiv|2025Cited by 1